Keyword: Vividion Therapeutics
Vividion, which is looking to boost the number of proteins small molecules can target, will advance three programs and expand its early-stage work.
The capital will push Revolution's lead program, a SHP2 inhibitor, into the clinic.
The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells used to break proteins apart.
R&D chief Narsimhan will replace retiring Jimenez as Novartis CEO, Stada names its fourth CEO in less than two years, Vertex poaches CFO from Ironwood.
Vividion Therapeutics seeks to deploy its synthetic and proteomic chemistry platforms to “dramatically expand” the number of targets that can be approached therapeutically. Its technology identifies previously unknown druggable targets in the human proteome.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.